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Abstract This study considered the problem of predicting survival, based
on three alternative models: a single Weibull, a mixture of Weibulls and a
cure model. Instead of the common procedure of choosing a single “best”
model, where “best” is defined in terms of goodness of fit to the data, a
Bayesian model averaging (BMA) approach was adopted to account for model
uncertainty. This was illustrated using a case study in which the aim was the
description of lymphoma cancer survival with covariates given by phenotypes
and gene expression. The results of this study indicate that if the sample size is
sufficiently large, one of the three models emerge as having highest probability
given the data, as indicated by the goodness of fit measure; the Bayesian
information criterion (BIC). However, when the sample size was reduced, no
single model was revealed as “best”, suggesting that a BMA approach would be
appropriate. Although a BMA approach can compromise on goodness of fit to
the data (when compared to the true model), it can provide robust predictions
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and facilitate more detailed investigation of the relationships between gene
expression and patient survival.
Keywords Bayesian modelling · Bayesian Model Averaging · Cure model ·
Markov Chain Monte Carlo · Mixture model · Survival analysis · Weibull
distribution
.
1 Introduction
Modelling survival data plays an important role in the application of statistics
in medicine and health science. In addition to a nonparametric formulation,
there are many parametric models available for describing survival, including
models based on a single distribution such as the Exponential and Weibull,
mixture models based for example on mixtures of distributions and a mixture
of susceptible and insusceptible individuals or so-called cure models which
account for a fraction of the patients being cured from the disease. Given the
wealth of models, the dilemma that is faced by many practitioners is the choice
of a survival model.
The problem of model selection is abundant throughout the literature.
This includes both covariate selection and choice of the model itself. Some of
the methods are based on a series of significance tests while others fit more
comprehensive models; some include prior information; some use analytic or
approximate methods of estimation while others use Markov Chain Monte
Carlo (MCMC) methods; different approaches use different optimisation or
model comparison criteria such as Bayes factors (Raftery, 1996). For example,
McGrory and Titterington (2007) showed how variational techniques can be
used to extend the deviance information criterion (DIC) to include the com-
parison of mixture models, while Basu and Tiwari (2010) used Bayes factors
to compare the various model structures in breast cancer survival data.
Recently, Bonato et al (2011) proposed Bayesian ensemble methods to
obtain better survival prediction in highdimensional gene expression data. Re-
gardless of the method, the most common approach is to choose a single model
based on the adapted optimisation or model choice criterion. However, if a sin-
gle model is selected, then inferences are conditional on the selected model,
and model uncertainty is ignored which often leads to excessively narrow or
misleading inferences (Raftery et al, 1997; Hjort and Claeskens, 2003). This
difficulty can be overcome by combining the information provided by all suit-
able models into the analysis. The most common way of achieving this is to
use a formof model averaging. From a Bayesian point of view, this averaging
is applied such that the posterior distribution of the quantity of interest is
obtained over the set of suitable models, weighted by the respective posterior
model probabilities (Raftery, 1996).
Draper (1995) and Raftery (1995) reviewed Bayesian model averaging
(BMA) and the cost of ignoring model uncertainty. Madigan and Raftery
(1994) also considered BMA by using Occam’s razor and Occam’s window
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approaches to reduce the number of candidate models. Yuan and Yin (2011)
used model averaging procedures to make more robust inferences regarding the
dose-finding design for phase I clinical trials. Pramana et al (2012) focused on
the case in which several parametric models are fitted to gene expression data
and discussed model averaging techniques for the estimation of dose-response
models.
In this paper, we consider the problem of predicting survival, based on
three alternatives models; a single Weibull, a mixture of Weibulls and a cure
model. The Weibull distribution is a popular parametric distribution for de-
scribing survival times (Dodson, 1994). Given the variety of shapes that can
be described by the probability density function (pdf) and the simple repre-
sentation of the survival function, theWeibull distribution has been used very
effectively for analysing lifetime data, particularly when the data are censored,
which is very common in most life testing experiments (Collet, 1994; Kundu,
2008). Given the nature of microarray data to describe biological systems and
outcomes of patients, and the potential of these covariates to produce more
precise inferences about survival, the use of a single parametric distribution
to describe survival time may not be adequate. Microarray data may enable
the description of several homogeneous subgroups of patients with respect to
survival time. This paper therefore also considered a mixture ofWeibull mod-
els for precise estimation and prediction of survival. Mixturemodels can be
used to describe a population consisting of several disjoint groups, where each
group is assigned its own distribution, weighted by the probability of an indi-
vidual from the overall population belonging to that group. This model thus
provides a convenient and flexible mechanism for identification and estimation
of distributions which are not well modelled by any standard parametric fam-
ily (Stephens, 1997). In the study considered here, the mixture is assumed to
comprise a known number of Weibull distributions, with potentially different
parameters.Most approaches to the analysis of time to event data implicitly
assume all individuals will experience the event of interest. However, there are
situations when a proportion of individuals are not expected to experience the
event of interest; that is, those individuals are often referred to as immune,
cured or nonsusceptible (Ibrahim et al, 2001). To address this issue, cure rate
models are considered, which are survival models incorporating a cure fraction.
These models, which can be considered as a form of mixture model with one
component degenerating to a point mass, extend the understanding of time
to event data by allowing the formulation of more accurate and informative
conclusions about the two groups of subjects.
Finally, instead of adopting the usual practice of choosing a single “best”
model, where “best” is defined in terms of the probability of the model given
the data, a BMA approach was adopted to account for model uncertainty in
the prediction of the response.We illustrate the approach using a microarray
dataset.
The paper is organised as follows. In Section 2, we define BMA. The three
competing models are described in a Bayesian framework in Section 3. The
computational approach for estimation is also presented in this section. In the
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Section 4, we illustrate the model using a case study. The results are discussed
further in Section 5.
2 Methods
The key elements of BMA were discussed by Raftery (1995). He suggested
weighting each model by the posterior model probabilities derived from a
Bayesian analysis. Assume that there are S models being considered, for
s = 1, 2, . . . , S, each with parameter set θs based on data D. Let ∆ be the
quantity of interest; this could represent, for example, the posterior predictive
distribution of y. Hence, the posterior distribution of ∆ given data D (Hoeting
et al, 1999) is
p(∆ | D) =
S∑
s=1
p(∆ | S = s,D)p(S = s | D),
where p(S = s | D) is the posterior probability of a particular model being
true, defined as
p(S = s | D) = p(D | S = s)p(S = s)∑S
s=1 p(D | S = s)p(S = s)
, s = 1, 2, . . . , S,
where p(D | S = s) = ∫ p(D | θs, S = s)p(θs | S = s)dθs.
Here, p(D | S = s) is the marginal likelihood of the data D given model
S = s and p(θs | S = s) is the prior density of θs given model S = s. p(S = s)
is the prior probability that model s is the true model (Hoeting et al, 1999).
Given a model selection problem in which we have to choose between two
models, the plausibility of the two different models S1 and S2 is assessed by
the Bayes factor as the ratio of posterior model probabilities.
The main detractor from using Bayes factors is that they are, in general,
difficult to compute. Raftery (1995) proposed using the Bayesian information
criterion (BIC) (Schwarz, 1978) as an approximation. Buckland et al (1997)
and Claeskens and Hjort (2008) discussed the utilization of BIC in BMA.
Buckland et al (1997) proposed simpler methods which weights are based
upon the penalized likelihood functions formed from the AIC (Akaike, 1973).
The starting point for Burnham and Anderson’s model selection theory
is the Kullback-Leibler (KL) information given by Burnham and Anderson
(2002) and Claeskens and Hjort (2008):
I(f | q) =
∫
f(x) log
f(x)
q(x | θs)dx,
where f represents the density function of the true and unknown model, q
represents the density function of the model that is used to approximate f , and
θs is a vector of the unknown parameters to be estimated. The notation I(f | q)
denotes the information lost when q is used to approximate f or the distance
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from q to f . For a given set of models, one can compare the KL information
for each model and select the model that minimizes the information loss across
the considered set of models (Burnham and Anderson, 2002, 2004). However,
in practice I(f | q) cannot be computed since the true model f is unknown.
Schwarz (1978) and Burnham and Anderson (2002) made the link between
the KL information and likelihood theory, and showed that the expected KL
information can be expressed as
E(KL) = − log p(D | θˆs, S = s) + ds log(n),
where p(D | θs) is the likelihood, ds is the number of parameters in the model
and n is the number of uncensored observations in a survival context (Volinsky
and Raftery, 2000). A Laplace approximation, typically the BIC (Schwarz,
1978), can be used to approximate p(D | S = s) (Clyde, 2000; Hoeting et al,
1999; Jackson et al, 2009; Yuan and Yin, 2011):
log (p(D | S = s)) ≈ log p(D | θˆs, S = s)− ds log(n),
BIC = −2 log p(D | θˆs, S = s) + ds log(n). (1)
Here log p(D | θˆs, S = s) is the maximised log-likelihood of model s, which
estimates goodness of fit of the data.
Schwarz (1978) and Burnham and Anderson (2002) proposed the likelihood
of the model given the data, using θˆs defined by
p(D | θˆs, S = s) ∝ e0.5×BIC . (2)
The BMA weight for the sth model (Yuan and Yin, 2011; Jackson et al,
2009) is therefore given by
p(S = s | D) = exp(−
1
2BICs)p(S = s)∑S
s=1 exp(− 12BICs)p(S = s)
.
The BMA weight can be interpreted as the weight of the evidence that
model s is true model given a set of S models. For the case in which there is
no information about prior probabilities, we can let p(S = s) be equal for all
candidate models (1/S), indicating no prior preference for any of the models
(Jackson et al, 2009; Pramana et al, 2012). The model with the largest BMA
weight will be considered as the best model. Therefore, p(S = s | D) is also
an approximation to the posterior probability of the model s being correct
(Schwarz, 1978). A smaller BIC value indicates a better model fit, accounting
for model complexity.
Let f˜sj be the j
th simulated observation from the sth model. Then the
mean of f from the BMA model, (f¯MA), can be calculated as follows
f¯MA =
 N∑
j=1
S∑
s=1
wsf˜sj
 /N,
where N is the number of simulated observations and ws = p(S = s | D) is
the BMA weight, defined previously.
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3 Models
3.1 Weibull Model
In this section, we define the Weibull model for analysing survival of patients
in the context of human health. We confine ourselves to survival times that are
the difference between a nominated start time and a declared failure (uncen-
sored data) or a nominated end time (censored time). Let T be a nonnegative
random variable for a person’s survival time and t be a realisation of the
random variable T . Kleinbaum and Klein (2005) give some reasons for the
occurrence of right censoring in survival studies, including termination of the
study, drop outs, or loss to follow-up. For the censored observations, one could
impute the missing survival times or assume that they are event-free. The
former is often difficult, especially if the censoring proportion is large, and
extreme imputation assumptions (such as all censored cases fail right after
the time of censoring) may distort inferences (Leung et al, 1997; Stajduhar
et al, 2009). In this study, we treat all censored cases as event-free regardless
of observation time.
Initially, we assume that we observe survival times t of patients possibly
from a heterogeneous population. The two-parameter Weibull density function
for survival time is given by
W (t | α, γ) = αγtα−1 exp (−γtα) ,
for α > 0 and γ > 0, where α is a shape parameter and γ is a scale parameter
(Ibrahim et al, 2001).
Since the logarithm of the Weibull hazard is a linear function of the loga-
rithm of time, it is more convenient to write the model in terms of the param-
eterisation λ = log(γ) (Ibrahim et al, 2001), so that:
f(t | α, λ) = αtα−1 exp(λ− exp(λ)tα),
where t > 0, α > 0 and γ > 0.
The corresponding survival function and the hazard function, using the λ
parameterization, are as follows:
S(t | α, λ) = exp(− exp(λ)tα),
h(t | α, λ) = f(t | α, λ)/S(t | α, λ) = α exp(λ)tα−1.
We now assume that we observe possibly right-censored data for n subjects;
y = (y1, . . . , yn) where yi = (ti, δi) and δi is an indicator function such that
(Marin et al, 2005a):
δi =
{
1, if the lifetime is uncensored, i.e., Ti = ti.
0, if the lifetime is censored, i.e., Ti > ti.
(3)
Let xij be the j
th covariate associated with ti for j = 1, 2, . . . , p+ 1. In our
case study, xij indicates the p gene expressions from DNA microarray data,
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and xi0 indicates the multi-category phenotype covariate. The data structure
is as follows: 
Survival time
t1
t2
...
tn


Category Gene 1 . . . Gene p
x10 x11 . . . x1p
x20 x21 . . . x2p
...
...
...
...
xn0 xn1 . . . xnp
 .
The gene expression data can be included in the model through λ (Tham-
rin et al, 2013). Given that λ must be positive, one option is to include the
covariates as follows:
γi = exp(x
′
iβ), so that
λi = log(γi) = x
′
iβ. (4)
Thus, the log-likelihood function becomes:
logL(α,β | D) =
n∑
i=1
δi
(
log(α) + (α− 1) log(ti)
+ x′iβ
)− exp(x′iβ)tαi .
We assume that (α, λ) are independent a priori (Marin et al, 2005a), and
assign Gamma distributions. Thus, the priors are now given by:
α ∼ Gamma(uα, vα)
λi ∼ Normal(x′iβ, σ2)
β ∼ Normal(0,Σ),
and we allow Σ to be diagonal with elements σ2j , j = 1, 2, . . . , p.
Diffuse priors are represented by large positive values for σ2, and small
positive values for uα and vα.
The joint posterior distribution of (α,β) is given by:
p(α, β | D) ∝ L(α,β | D)p(α)p(β)
∝ αα0+d−1 exp
{
n∑
i=1
(δix
′
iβ + δi (α− 1) log (ti)− tαi exp (x′iβ))
−b0α− 1
2
(β − µ0)Σ−10 (β − µ0)
}
,
where d =
∑n
i δi.
MCMC analysis is performed by sampling from the conditional distribu-
tions of the parameters. The conditional distribution of α does not have an
explicit form but can be sampled from MCMC algorithms such as Metropolis
Hastings or slice sampling (Gilks et al, 1996).
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3.2 Weibull Mixture Model
We define the Weibull mixture model for analysing survival data. A mixture
of K Weibull densities (Marin et al, 2005a) is defined by
f(t | K,w,α,γ) =
K∑
m=1
wmW (t | αm, γm), (5)
where α = (α1, . . . , αK), γ = (γ1, . . . , γK) are the parameters of each Weibull
distribution and w = (w1, . . . , wK) is a vector of nonnegative weights which
sum to one.
The corresponding survival function S(t | K,w,α,γ) and hazard function
h(t | K,w,α,γ) are as follows:
S(t | K,w,α,γ) =
K∑
m=1
wm exp (−γmtαm) ,
h(t | K,w,α,γ) = f(t | K,w,α,γ)/S(t | K,w,α,γ).
We now assume that we observe possibly right-censored data for n patients;
y = (y1, . . . , yn) where yi = (ti, δi) and δi is an indicator function as described
in Section 3.1.
Let xij be the j
th covariate associated with patient i, for j = 1, 2, . . . , p.
In our application, xij could indicate, for example, the gene expressions. The
covariates can be included in the model as follows (Farmomeni and Nardi,
2010)
log(γm) = x
′
iβm = λm, (6)
where xi = (xi1, . . . , xip), γm = (γ1m, . . . , γpm) and βm = (β1m, . . . , βpm), for
i = 1, 2, . . . , n and m = 1, 2, . . . ,K.
Thus, the likelihood function becomes:
L (w,α,γ | K, ti, δi,x) ∝
n∏
i=1
[
f (ti | K,w,α,γ,x)δi S (ti | K,w,α,γ,x)1−δi
]
Here, the incomplete information is modelled via the survivor function,
which reflects the probability that the patient was alive for duration greater
than ti.
The following prior distributions are placed on the parameters w and α:
w | K ∼ Dirichlet(φ1, . . . , φK), φm = φ, ∀m = 1, 2, . . . ,K.
αm ∼ Gamma(uα, vα),m = 1, 2, . . . ,K.
For a model without covariates, we employ the following prior for γm:
γm ∼ Gamma(uγ , vγ),m = 1, 2, . . . ,K.
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We chose small positive values for uα, vα, uγ , vγ to express vague prior
knowledge about these parameters and we set φ = 1 (Marin et al, 2005a). For
a model with covariates, we employ a multivariate normal prior on βm, so that
βm | K ∼ N(0,Σ),
and we allow Σ to be diagonal with elements σ2j , j = 1, 2, . . . , p. Again, we ex-
press a vaguely informative prior by setting a large positive value for σ2j . Again,
we express a vaguely informative prior by setting a large positive value for σ2j
. The diagonal matrices were used here but this changed recently (Bhadra
and Mallick., 2013), so one may argue that a non-diagonal variace-covariance
matrix may be more appropriate.
The model described in this section can be fitted using MCMC sampling
with latent values Zi to indicate component membership of the i
th observation
(Diebolt and Robert, 1994; Robert and Casella, 2000). Since wm = Pr(Zi =
m), we can write Zi ∼M(w1, . . . , wK). In this scheme, the Zi are sampled by
computing posterior probabilities of membership, and the other parameters
are sampled from their full conditional distributions. This was implemented
in the WinBUGS software package (Spiegelhalter et al, 2002).
The WinBUGS software (Lunn et al, 2000; Ntzoufras, 2009; Spiegelhal-
ter et al, 2002) is an interactive Windows version of the BUGS program for
Bayesian analysis of complex statistical models using MCMC techniques.
Label switching, caused by non-identifiability of the mixture components,
was dealt with post-MCMC using the reordering algorithm of Marin et al
(2005b). The algorithm proceeded by selecting the permutation of compo-
nents at each iteration that minimised the vector dot product with the so-called
“pivot”, a high density point from the posterior distribution. The MCMC out-
put was then reordered according to each selected permutation. In this paper,
the approximate maximum a posteriori (MAP) (i.e. the realization of param-
eters corresponding to the MCMC iterate that maximised the unnormalised
posterior) was chosen as the pivot.
3.3 Cure Model
As in Section 3.1, we observe time to the event of interest for n independent
subjects, and we let (ti, δi) denote the observed time and the event indica-
tor for the i-th observation. Let S1(t) be the survivor function for the entire
population, S∗(t) be the survivor function for the non-cured group in the pop-
ulation, and pi be the cure rate function. Then the standard cure rate model
is given by:
S1(t) = pi + (1− pi)S∗(t). (7)
The commonly used parametric distributions include Exponential and Weibull
for S∗(t).
As in Yakovlev and Tsodikov (1996), Chen et al (1999) and Ibrahim et al
(2001), for an individual in a population, let N denote the number of latent
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variables. Assume that N has a Poisson distribution with mean θ. Let Zi, i =
1, . . . , N denote the random time, where Zi are independently and identically
distributed (i.i.d.) with a common distribution function F (t) = 1−S(t). Also,
assume that Zi are independent of N . The time to event can be defined by
the random variable Y = min(Zi, 0 ≤ i ≤ N), where P (Z0 = ∞) = 1. Hence,
the survival function for the population is given by
Spop(t) = P (N = 0) + P (Z1 > t, . . . , ZN > t,N ≥ 1)
= exp(−θ) +
∞∑
k=1
[S(t)]k
θk
k!
exp(−θ)
= exp(−θF (t)). (8)
A corresponding cure fraction in model (8) is limt→∞ Spop(t) = exp(−θ) > 0.
We also know from (8) that the cure fraction is given by Spop(∞) = P (N =
0) = exp(−θ). As θ → ∞, the cure fraction tends to 0, whereas as θ → 0,
the cure fraction tends to 1. Corresponding population density and hazard
functions are fpop(t) = − ddtSpop(t) = θf(t) exp(−θF (t)) and hpop(t) = θf(t),
respectively.
The proportional hazards structure with the covariates is modelled through
θ (Chen et al, 1999; Ibrahim et al, 2001). The population survival function (8)
can be written as
Spop(t) = exp(−θ) + [1− exp(−θ)]S∗(t),
where S∗(t) = exp(−θF (t))−exp(−θ)1−exp(−θ) , and f
∗(t) = exp(−θF (t))1−exp(−θ) θf(t).
Following Chen et al (1999) and Ibrahim et al (2001), we construct the
likelihood function. Suppose we have n subjects and we assume that the Ni are
i.i.d with Poisson distributions with means θi, i = 1, . . . , n. Let Zi1, . . . , ZiN
denote the times for theNi competing causes, which are unobserved, and which
have a cumulative distribution function, F (.). In this section, we will specify
a parametric form for F (.) that is a Weibull distribution. Let ψ = (α, λ)
′
,
where α is the shape parameter and λ is the scale parameter. We incorporate
covariates for the cure rate model through the cure parameter θ and we have
a different cure rate parameter, θi, for each subject.
Let x
′
i = (xi1, . . . , xik) denote the k x 1 vector of covariates for the ith
subject, and let β = (β1, . . . , βk) denote the corresponding vector of regression
coefficients. We relate θ to the covariates by θi = exp(x
′
iβ). Let ti denote the
survival time for subject i, which is right censored, let Ci be the censoring
time, and let δi be the censoring indicator, assuming 1 if Ti is a failure time
and 0 if it is right censored. The observed data are D = (n, t, δ,X), where
t = (t1, . . . , tn)
′
, δ = (δ1, . . . , δn)
′
and X = (x1, . . . , xn)
′
. The complete data
are given by Dc = (n, t, δ,X,N), where N = (N1, . . . , Nn)
′
. The complete-
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data likelihood function of the parameter (ψ,β) can be written as
L(ψ,β | Dc) =
{
n∏
i=1
S(ti | ψ)Ni−δi(Nif(ti | ψ))δi
}
× exp
{
n∑
i=1
Ni log(θi)− log(Ni!)− nθi
}
. (9)
Again, we assume independent priors for β and ψ, where α ∼ Gamma(aα, bα),
λ ∼ N(µλ,Σλ) and β ∼ N(µβ ,Σβ). We also assume p(α, λ) = p(α |
δ0, τ0)p(λ), p(α | δ0, τ0) ∝ αδ0−1 exp(−τ0α), and the hyperparameters (δ0, τ0)
are specified (Chen et al, 1999; Ibrahim et al, 2001).
Combining these specifications with the likelihood function (9), the joint
posterior distribution of (α, λ,β) becomes
p(α, λ,β | D) ∝
n∏
i=1
(θif(ti | α, λ))δi exp(−θi(1− S(ti | α, λ)))
×p(α | δ0, τ0)p(α, λ)p(β). (10)
The joint posterior density of (α, λ,β) in equation (10) is analytically in-
tractable because the integration of the joint posterior density is not easy to
perform. Hence, inferences are based on MCMC simulation methods. We can
use, for example, the Metropolis-Hastings algorithms or slice sampling to sim-
ulate samples of α, λ and β. MCMC computations were implemented using
the WinBUGS system (Spiegelhalter et al, 2002).
4 Application to Gene Expression Data
4.1 DLBCL Dataset
We applied the proposed method of model averaging across the three candidate
survival models to a dataset containing gene expression of Diffuse Large B-cell
Lymphoma (DLBCL). The dataset comprises gene expression measurements
and survival times of patients with DLBCL (Rosenwald et al, 2002). DLBCL
(Lenza et al, 2008) is a type of cancer of the lymphatic system in adults which
can be cured by anthracycline-based chemotherapy in only 35 to 40 percent
of patients (Rosenwald et al, 2002). In general, types of this disease are very
diverse and their biological properties are largely unknown, meaning that this
is a relatively difficult cancer to cure and prevent. Rosenwald et al (2002)
proposed that there are three phenotypes subgroups of patients of DLBCL:
activated B-like DLBCL, germinal centre (GC)-B like and type III DLBCL.
The GC B-like DLBCL is less dangerous than the others in the progression of
the tumour; the activated B-like DLBCL is more active than the others and the
type III DLBCL is the most dangerous in the progression of tumour (Alizadeh
et al, 2000). These groups were defined using microarray experiments and hi-
erarchical clustering. The authors showed that these phenotypes subgroups
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were differentiated from each other by distinct gene expressions of hundreds of
different genes and had different survival time patterns. This dataset contains
219 patients with DLBCL, including 138 patient deaths during follow-up. Pa-
tients with missing values for a particular microarray element were excluded
from all analyses involving that element.
Based on patterns of gene expression in biopsy specimens of the lymphoma,
Rosenwald et al (2002) analysed this dataset to predict the likelihood of pa-
tients’ survival after chemotherapy for DLBCL. By using a Cox proportional-
hazards model, Rosenwald et al (2002) identified five individual gene expres-
sions which correlated with the survival after chemotherapy. These gene ex-
pressions are germinal center B-cell (GC-B), lymphoma node, proliferation,
BMP6 and MHC. In this study, these five gene expressions are used as co-
variates for estimating survival times based on the three competing models in
Section 3.
Fig. 1 Kaplan-Meier estimates of overall survival according to the gene-expression sub-
groups.
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4.2 Results
As discussed in Section 2, to account for model uncertainty, the model aver-
aging technique which combines estimates from different survival models was
carried out. This was accomplished through a weighted average of the survival
considered in the analysis. First, we calculated the Kaplan-Meier estimates of
overall survival according to the gene expression and the relation between the
gene expression score and the subgroups phenotype of DLBCL. We confirmed
that these phenotypes had different survival time patterns (Figure 1). Follow-
ing this, we fitted the three models to all gene expression data and to the
three phenotype subgroups. We then applied the BMA approach described in
Section 2. For each model, we ran the corresponding MCMC algorithm for 100
000 iterations, discarding the first 10 000 iterations as burn-in.
Table 1 The estimated posterior mean of the parameters, the 95% credible intervals (CI),
the BIC values and the BMA weights for each of the fitted models for the full DLBCL
dataset.
Model Parameter Mean 95% CI BIC Weight
Weibull α 0.7305 (0.626,0.840) 687.0953 0.0009
β0 -1.578 (-1.84, -1.33)
β1 -0.3446 (-0.516, -0.172)
β2 -0.2844 (-0.454, -0.116)
β3 0.2097 (-0.049, 0.468)
β4 0.3292 (0.115, 0.537)
β5 -0.3019 (-0.488, -0.112)
Mixture α1 4.029 (2.411, 6.631) 734.0054 ≈ 0
α2 0.7707 (0.662, 0.885)
β01 6.857 (5.479, 8.205)
β02 -1.724 (-2.007, -1.457)
β11 -11.62 (-12.88, -10.35)
β12 -0.3956 (-0.575, -0.216)
β21 -2.087 (-3.54, -0.689)
β22 -0.3172 (-0.495, -0.143)
β31 -2.241 (-3.425, -1.059)
β32 0.1972 (-0.064, 0.461)
β41 -0.2849 (-1.434, 0.854)
β42 0.3594 (0.141, 0.574)
β51 -0.7928 (-2.107, 0.477)
β52 -0.3102 (-0.500, -0.115)
pi1 0.01992 (0.002, 0.053)
pi2 0.9801 (0.946, 0.997)
Cure α 0.9884 (0.828, 1.145) 673.1359 0.9991
β0 0.1611 (-0.124, 0.560)
β1 -0.3151 (-0.484, -0.144)
β2 -0.2821 (-0.451, -0.115)
β3 0.189 (-0.070, 0.442)
β4 0.3303 (0.118, 0.539)
β5 -0.3039 (-0.490, -0.112)
Table 1 shows the estimated posterior mean of the parameters, the 95%
credible intervals (CI), the BIC values and the BMA weights for each of the
fitted models for the whole dataset. The BMA weights reflect the relative
posterior probability of the models. As can be seen from Table 1, for the
Weibull model, there are three genes that substantially describe patients’ sur-
vival times, namely GC-B (β1), lymphoma node (β2) and MHC (β5). These
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three genes have a negative effect on the expected survival time. For the mix-
ture model, GC-B (β1), lymphoma node (β2) and proliferation (β3) accounted
for patients’ survival times in the first component. In the second component,
GC-B (β1), lymphoma node (β2) and MHC signature (β5) substantially ex-
plained patients’ survival times. All these genes have negative effects on the
expected survival time for their respective component. For the cure model,
four of these genes substantially describe patients’ survival times, namely GC-
B (β1), lymphoma node (β2), BMP6 (β4) and MHC (β5) signature. Three
of these, namely GC-B (β1), lymphoma node (β2) and MHC signature (β5),
have a negative effect on the expected survival time. Under the cure model,
approximately 33.8% of the patients are cured of DLBCL (Figure 2).
This is clearly exhibited in Table 1, which shows that the cure model has the
largest posteriormodel probability (or BMA weight). To evaluate the model
fit, a comparison of predicted values under the models and of the observed
data was carried out.
Fig. 2 Box-plots of the cure rates (posterior distribution of pi) for the full DLBCL dataset,
and to each of the three phenotypes (ABC, GCB and Type III).
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Table 2 The estimated posterior mean of parameters, the 95% CI, BIC values and the
BMA weights for each of the models based on phenotype for the DLBCL dataset.
Phenotype Model Variable Parameter Mean 95% CI BIC Weight
GCB Weibull α 0.692 (0.5365, 0.8595) 341.212 0.497
Intercept β0 -1.649 (-2.185, -1.17)
GCB β1 -0.179 (-0.5859, 0.239)
Lymphoma β2 -0.118 (-0.3958, 0.1607)
Proliferation β3 0.459 (-0.0306, 0.934)
BMP6 β4 0.414 (0.01773, 0.809)
MHC β5 -0.325 (-0.6389, -0.01228)
Mixture α1 4.252 (2.591, 7.175) 377.759 ≈ 0
α2 0.816 (0.6209, 1.032)
Intercept β01 6.491 (5.246, 7.781 )
β02 -2.152 (-2.798, -1.567)
GCB β11 -11.81 (-13.05, -10.53)
β12 -0.030 (-0.5104, 0.4592)
Lymphoma β21 -1.839 (-3.082, -0.6744)
β22 -0.134 (-0.48, 0.2254)
Proliferation β31 -2.165 (-3.313, -0.9932)
β32 0.588 (-0.07796, 1.407)
BMP6 β41 -0.242 (-1.357, 0.8482)
β42 0.654 (0.17, 1.161)
MHC β51 -0.629 (-1.993, 0.5117)
β52 -0.382 (-0.7687, -0.002227)
φ1 0.090 (0.02007, 0.1863)
φ2 0.91 (0.8137, 0.9799)
Cure α 0.845 (0.6075, 1.1) 341.188 0.503
Intercept β0 0.604 (-0.3556, 3.394)
GCB β1 -0.173 (-0.5754, 0.2402)
Lymphoma β2 -0.116 (-0.3891, 0.1579)
Proliferation β3 0.433 (-0.0522, 0.9041)
BMP6 β4 0.396 (-0.0007, 0.788)
MHC β5 -0.330 (-0.6422, -0.0209)
ABC Weibull α 0.894 (0.695, 1.115) 215.564 0.013
Intercept β0 -1.86 (-2.562, -1.217)
GCB β1 -0.509 (-0.9948, -0.03871)
Lymphoma β2 -0.626 (-0.9568, -0.3099)
Proliferation β3 -0.487 (-1.118, 0.1422)
BMP6 β4 0.645 (0.2725, 1.021)
MHC β5 -0.479 (-0.7955, -0.1598)
Mixture α1 2.427 (1.083, 4.152) 256.552 ‘ ≈ 0
α2 0.960 (0.7525, 1.189)
Intercept β01 6.636 (5.301, 7.959)
β02 -2.572 (-3.346, -1.865)
GCB β11 -12.11 (-13.36, -10.86)
β12 -0.925 (-1.438, -0.4356)
Lymphoma β21 -3.155 (-4.578, -1.75)
β22 -0.768 (-1.114, -0.4341)
Proliferation β31 -2.377 (-3.561, -1.188)
β32 -0.480 (-1.099, 0.1353)
BMP6 β41 0.079 (-1.064, 1.232)
β42 0.690 (0.3249, 1.061)
MHC β51 -0.644 (-1.919, 0.6499)
β52 -0.515 (-0.8176, -0.2047)
φ1 0.037 (0.0046, 0.09883)
φ2 0.963 (0.9012, 0.9953)
Cure α 1.189 (0.8906, 1.483) 206.961 0.987
Intercept β0 0.019 (-0.6417, 0.7362)
GCB β1 -0.432 (-0.8874, 0.01376)
Lymphoma β2 -0.587 (-0.905, -0.2867)
Proliferation β3 -0.484 (-1.076, 0.1012)
BMP6 β4 0.607 (0.2557, 0.9631)
MHC β5 -0.446 (-0.7481, -0.1346)
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Phenotype Model Variable Parameter Mean 95% CI BIC Weight
Type III Weibull α 0.834 (0.5958, 1.101) 162.27 0.538
Intercept β0 -1.75 (-2.736, -0.9093)
GCB β1 -0.404 (-1.028, -0.19)
Lymphoma β2 -0.274 (-0.7404, 0.1644)
Proliferation β3 0.506 (-0.0897, 1.084)
BMP6 β4 0.017 (-0.5301, 0.5206)
MHC β5 -0.199 (-0.6839, 0.3098)
Mixture α1 11.82 (8.609, 15.14) 196.271 ≈ 0
α2 0.596 (0.43, 0.7757)
Intercept β01 6.002 (3.682, 8.336)
β02 -5.005 (-7.19, -2.812)
GCB β11 -9.32 (-12.02, -6.611)
β12 0.564 (0.1829, 1.004)
Lymphoma β21 -2.913 (-5.716, -0.02716)
β22 -0.558 (-1.015, -0.1525)
Proliferation β31 -2.021 (-4.547, 0.455)
β32 0.893 (0.3455, 1.515)
BMP6 β41 0.320 (-2.466, 3.373)
β42 0.140 (-0.2735, 0.5384)
MHC β51 -0.336 (-2.733, 2.323)
β52 -0.293 (-0.7741, 0.1504)
φ1 0.072 (0.0108, 0.1805)
φ2 0.928 (0.8195, 0.9891)
Cure α 0.969 (0.6534, 1.339) 162.578 0.462
Intercept β0 0.989 (-0.5077, 4.153)
GCB β1 -0.349 (-0.973, -0.25)
Lymphoma β2 -0.269 (-0.7375, 0.1687)
Proliferation β3 0.502 (-0.0955, 1.084)
BMP6 β4 0.046 (-0.4801, -0.1801)
MHC β5 -0.183 (-0.6625, 0.3207)
Table 2 shows the 95% credible interval (CI), BIC values and the BMA
weights for each of the models based on phenotype for the DLBCL dataset. In
general, for all phenotypes, the mixture model is not favourable as its weight
is approximately equal to zero and it has the largest BIC value. On the other
hand, the BIC values of the other two models are close to each other, suggesting
a combination of these two models in order to account for the uncertainty in
the prediction of survival.
From Tables 1 and 2, we can see that the Weibull model is better than a
two-component Weibull mixture model.
As can be seen in Figure 3, in the full DLBCL dataset, the predicted curve
for the cure model is quite close to the observed data, suggesting a good fit
of the data. Specifically, in this model, 94.35% of observed survival times in
the dataset fall in the corresponding 95% posterior prediction intervals. As
expected, this is quite similar to the result obtained from model averaging
(91.93%) (Table 3).
Table 3 The percentage of observed values that lay in the corresponding 95% posterior
prediction for the individual models and BMA model based on the full DLBCL dataset and
each of the three phenotypes.
Model All DLBCL GCB ABC Type III
Weibull 87.51 90 89.13 89.28
Mixture 85.90 88 86.95 82.14
Cure 94.35 92 91.30 85.71
BMA 91.93 94 93.47 92.85
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Furthermore, in the GCB phenotype, the genes corresponding to the BMP6
(β4) and MHC signature (β5) in the Weibull model and MHC signature (β5)
in the cure model substantially affect patients’ survival time. In the ABC
phenotype, in the Weibull model, with the exception of proliferation (β3),
all genes were involved substantially in the description of patients’ survival
and lymphoma node (β2), BMP6 (β4)and MHC signature (β5) are potentially
important prognostic factors for predicting survival in the cure model. For the
type III phenotype, the GC-B gene (β1) in both models and only the BMP6
gene (β4) in the cure model are substantial in explaining the survival times of
the patients.
Fig. 3 The posterior densities of the three models and the model averaged density for the
full DLBCL dataset and each of the three phenotypes. For comparison, the observed data
is also represented as a histogram.
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Under the cure model, in the GCB phenotype, approximately 33.2% of
the patients are estimated to be cured of DLBCL. In the ABC and type III
phenotypes, the respective cure rates are approximately 26.57% and 18.7%
(Figure 2).
The results of the posterior densities prediction for the individual models
and the model averaged prediction based on these three phenotypes are pre-
sented in Figure 3. In comparison to other models, the mixture model fitted
the data poorly for each phenotype. In detail, using model averaging, for the
GCB phenotype, 94% of the observed survival times in the dataset lie in the
respective 95% prediction intervals. For the other two phenotypes, namely the
ABC and the type III, 93.47% and 92.85% of the observed survival times in the
dataset are in the corresponding 95% prediction intervals, respectively (Table
3).
5 Discussion
This study has adopted a Bayesian model averaging approach to account for
model uncertainty in the prediction of survival. The case study that we consid-
ered involved lymphoma cancer survival, with covariates given by phenotypes
and gene expressions. Here, we proposed three competing models and used
BMA to combine these models to account for model uncertainty.
Overall, the results of this study indicate that if using the full dataset
without further grouping, selecting a single model that best fits the data was
adequate. The reason is that there is clear support for one model (i.e. only one
model has a relatively larger BIC value and dominates based on this criterion).
However, the results were different when the model selection process took into
account the phenotype subgroups of the patients. A single model appeared to
be inadequate. This was due to the fact that the values of BIC for the Weibull
and the cure had nearly equal weight, indicating the absence of a dominant
model based on this criterion and the presence of uncertainty issues in the
model selection. As suggested and shown in this study, BMA was used to
address this problem. The applicability of BMA was also associated with the
smaller sample size in each phenotype subgroup (Yeung et al, 2005; Volinsky
et al, 1997; Annest et al, 2009).
This study also revealed that in each phenotype, the expression and number
of predictor genes substantially describing the survival times of the patients
varied across models. Overall, in both of the favourable models, none of the
genes were identified consistently as substantial predictors for the patients’
survival. For example, in the Weibull model, the MHC and BMP genes in
the GCB and ABC phenotypes and the GCB genes in the ABC and Type
III phenotypes were important predictors of survival. In contrast, in the cure
model, BMP was substantially associated with predicted survival in the ABC
and Type III phenotypes. For both models, only three genes i.e. lymphoma
node, BMP6 and MHC signature in the ABC phenotype were highly associated
with the survival times of the patients.
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This study has indicated that the application of BMA to combine com-
peting models overcomes the problem of model uncertainty. Comparison of
different survival models has allowed the identification and analysis of more
detailed relationships between gene expressions in given phenotypes and the
survival times of the patients. An advantage of BMA is more accurate and
precise prediction of patient survival. However, this study only involved three
candidate models. More models can be obviously included in the analysis.
This study has also focused on the marginal likelihood p(D | Qs) estimation
methods based on the Laplace approximation. However, other approaches are
also possible. Indeed marginal likelihood estimation is possible using nested
sampling (Skilling, 2006), where the marginal likelihood is viewed as the ex-
pectation, with respect to the prior, of the likelihood. Another generic is Chib’s
method (Chib, 1995), which can be applied to output from the Gibbs sampler.
Applying BMA to other datasets or other applications is desired to obtain
robust predictions.
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